Amneal Pharmaceuticals Statistics
Total Valuation
AMRX has a market cap or net worth of $1.71 billion. The enterprise value is $4.36 billion.
| Market Cap | 1.71B |
| Enterprise Value | 4.36B |
Important Dates
The next confirmed earnings date is Friday, May 3, 2024, before market open.
| Earnings Date | May 3, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AMRX has 308.55 million shares outstanding. The number of shares has increased by 16.69% in one year.
| Shares Outstanding | 308.55M |
| Shares Change (YoY) | +16.69% |
| Shares Change (QoQ) | +10.30% |
| Owned by Insiders (%) | 59.78% |
| Owned by Institutions (%) | 29.02% |
| Float | 123.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.04 |
| PS Ratio | 0.71 |
| Forward PS | 0.67 |
| PB Ratio | 86.42 |
| P/FCF Ratio | 5.72 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.96, with an EV/FCF ratio of 14.60.
| EV / Earnings | n/a |
| EV / Sales | 1.82 |
| EV / EBITDA | 11.96 |
| EV / EBIT | 32.28 |
| EV / FCF | 14.60 |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 139.05.
| Current Ratio | 1.63 |
| Quick Ratio | 0.84 |
| Debt / Equity | 139.05 |
| Debt / EBITDA | 7.55 |
| Debt / FCF | 9.21 |
| Interest Coverage | 0.64 |
Financial Efficiency
Return on equity (ROE) is -34.90%.
| Return on Equity (ROE) | -34.90% |
| Return on Assets (ROA) | -2.30% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $310,858 |
| Profits Per Employee | -$10,908 |
| Employee Count | 7,700 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.83 |
Taxes
In the past 12 months, AMRX has paid $8.45 million in taxes.
| Income Tax | 8.45M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +235.76% in the last 52 weeks. The beta is 1.35, so AMRX's price volatility has been higher than the market average.
| Beta (1Y) | 1.35 |
| 52-Week Price Change | +235.76% |
| 50-Day Moving Average | 5.71 |
| 200-Day Moving Average | 4.65 |
| Relative Strength Index (RSI) | 42.61 |
| Average Volume (30 Days) | 1,509,830 |
Short Selling Information
The latest short interest is 2.40 million, so 0.78% of the outstanding shares have been sold short.
| Short Interest | 2.40M |
| Short Previous Month | 1.83M |
| Short % of Shares Out | 0.78% |
| Short % of Float | 1.94% |
| Short Ratio (days to cover) | 1.30 |
Income Statement
In the last 12 months, AMRX had revenue of $2.39 billion and -$83.99 million in losses. Loss per share was -$0.48.
| Revenue | 2.39B |
| Gross Profit | 820.57M |
| Operating Income | 189.88M |
| Pretax Income | -75.54M |
| Net Income | -83.99M |
| EBITDA | 364.49M |
| EBIT | 135.09M |
| Loss Per Share | -$0.48 |
Balance Sheet
The company has $99.11 million in cash and $2.75 billion in debt, giving a net cash position of -$2.65 billion or -$8.59 per share.
| Cash & Cash Equivalents | 99.11M |
| Total Debt | 2.75B |
| Net Cash | -2.65B |
| Net Cash Per Share | -$8.59 |
| Equity / Book Value | 19.78M |
| Book Value Per Share | 0.06 |
| Working Capital | 531.27M |
Cash Flow
In the last 12 months, operating cash flow was $345.58 million and capital expenditures -$46.80 million, giving a free cash flow of $298.78 million.
| Operating Cash Flow | 345.58M |
| Capital Expenditures | -46.80M |
| Free Cash Flow | 298.78M |
| FCF Per Share | $1.70 |
Margins
Gross margin is 34.28%, with operating and profit margins of 7.93% and -3.51%.
| Gross Margin | 34.28% |
| Operating Margin | 7.93% |
| Pretax Margin | -3.16% |
| Profit Margin | -3.51% |
| EBITDA Margin | 15.23% |
| EBIT Margin | 5.64% |
| FCF Margin | 12.48% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.69% |
| Shareholder Yield | -16.69% |
| Earnings Yield | -4.91% |
| FCF Yield | 17.48% |
Analyst Forecast
The average price target for AMRX is $7.31, which is 31.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.31 |
| Price Target Difference | 31.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 3.30% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMRX has an Altman Z-Score of 1.1 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.1 |
| Piotroski F-Score | 4 |